Previous 10 | Next 10 |
EAGAN, Minn., May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ende...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop optimal cancer therapies, today announced that Theresa Ferguson has been named senior director of marketing. As the company’s senior marketing l...
EAGAN, Minn., April 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director of Marketing. As Predictive Oncology’s senior marketing leader, Ferguson steps in as the company begins commercialization of i...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its financial and corporate results for the year ended Dec. 31, 2021. Highlights of the report include p...
Predictive Oncology press release (NASDAQ:POAI): FY GAAP EPS of -$0.36 misses by $0.12. Revenue of $1.42M (+13.6% Y/Y) misses by $2M. Shares -2.66% AH. For further details see: Predictive Oncology GAAP EPS of -$0.36 misses by $0.12, revenue of $1.42M misses by $2M
EAGAN, Minn., March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended Decembe...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had reached a key milestone toward monetizing its unique approach to leverage AI in oncology drug d...
MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) achieved a key milestone toward monetizing its unique approach to leverage artificial intelligence (AI) in oncology drug discovery. Earlier this year, Predictive Oncology’s Discovery 21 proof-of-concep...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is focused on establishing a position as a first mover in the artificial intelligence (“AI”)-powered, d...
MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...